BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: af Björkesten C, Nieminen U, Sipponen T, Turunen U, Arkkila P, Färkkilä M. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scandinavian Journal of Gastroenterology 2013;48:543-51. [DOI: 10.3109/00365521.2013.772230] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Mojtahed A, Gee MS. Magnetic resonance enterography evaluation of Crohn disease activity and mucosal healing in young patients. Pediatr Radiol 2018;48:1273-9. [PMID: 30078049 DOI: 10.1007/s00247-018-4107-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
2 Yzet C, Diouf M, Le Mouel JP, Brazier F, Turpin J, Loreau J, Dupas JL, Peyrin-Biroulet L, Fumery M. Complete Endoscopic Healing Associated With Better Outcomes Than Partial Endoscopic Healing in Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2020;18:2256-61. [PMID: 31743755 DOI: 10.1016/j.cgh.2019.11.025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
3 Kopylov U, Yablecovitch D, Lahat A, Neuman S, Levhar N, Greener T, Klang E, Rozendorn N, Amitai MM, Ben-Horin S, Eliakim R. Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease Using Biomarkers, Capsule Endoscopy, and Imaging. Am J Gastroenterol. 2015;110:1316-1323. [PMID: 26215531 DOI: 10.1038/ajg.2015.221] [Cited by in Crossref: 86] [Cited by in F6Publishing: 84] [Article Influence: 14.3] [Reference Citation Analysis]
4 Ordás I, Rimola J, Rodríguez S, Paredes JM, Martínez-pérez MJ, Blanc E, Arévalo JA, Aduna M, Andreu M, Radosevic A, Ramírez-morros AM, Pinó S, Gallego M, Jauregui-amezaga A, Ricart E, Panés J. Accuracy of Magnetic Resonance Enterography in Assessing Response to Therapy and Mucosal Healing in Patients With Crohn's Disease. Gastroenterology 2014;146:374-382.e1. [DOI: 10.1053/j.gastro.2013.10.055] [Cited by in Crossref: 227] [Cited by in F6Publishing: 208] [Article Influence: 32.4] [Reference Citation Analysis]
5 Molander P, Färkkilä M, Ristimäki A, Salminen K, Kemppainen H, Blomster T, Koskela R, Jussila A, Rautiainen H, Nissinen M, Haapamäki J, Arkkila P, Nieminen U, Kuisma J, Punkkinen J, Kolho K, Mustonen H, Sipponen T. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? Journal of Crohn's and Colitis 2014. [DOI: 10.1016/j.crohns.2014.06.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
6 Barré A, Colombel JF, Ungaro R. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease. Aliment Pharmacol Ther 2018;47:896-905. [PMID: 29430672 DOI: 10.1111/apt.14550] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 21.3] [Reference Citation Analysis]
7 Shavrov A, Kharitonova AY, Davis EM, Claggett B, Morozov DA, Brown DK, Shavrov AA, Liu JJ. A Pilot Study of Confocal Laser Endomicroscopy to Predict Barrier Dysfunction and Relapse in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2016;62:873-8. [PMID: 26513619 DOI: 10.1097/MPG.0000000000001022] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
8 Vaughn BP, Shah S, Cheifetz AS. The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol 2014;12:103-17. [PMID: 24395615 DOI: 10.1007/s11938-013-0008-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
9 Kessel C, Lavric M, Weinhage T, Brueckner M, de Roock S, Däbritz J, Weber J, Vastert SJ, Foell D. Serum biomarkers confirming stable remission in inflammatory bowel disease. Sci Rep 2021;11:6690. [PMID: 33758351 DOI: 10.1038/s41598-021-86251-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
10 Morise K, Ando T, Watanabe O, Nakamura M, Miyahara R, Maeda O, Ishiguro K, Hirooka Y, Goto H. Clinical utility of a new endoscopic scoring system for Crohn’s disease. World J Gastroenterol 2015; 21(34): 9974-9981 [PMID: 26379402 DOI: 10.3748/wjg.v21.i34.9974] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
11 Plevris N, Fulforth J, Lyons M, Siakavellas SI, Jenkinson PW, Chuah CS, Lucaciu L, Pattenden RJ, Arnott ID, Jones G, Lees CW. Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn’s Disease. Clinical Gastroenterology and Hepatology 2021;19:1835-1844.e6. [DOI: 10.1016/j.cgh.2020.08.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
12 Shah SC, Colombel JF, Sands BE, Narula N. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther. 2016;43:317-333. [PMID: 26607562 DOI: 10.1111/apt.13475] [Cited by in Crossref: 154] [Cited by in F6Publishing: 131] [Article Influence: 25.7] [Reference Citation Analysis]
13 D'Haens G, Kelly O, Battat R, Silverberg MS, Laharie D, Louis E, Savarino E, Bodini G, Yarur A, Boland BS, Afif W, Li XJ, Hale M, Ho J, Kondragunta V, Huang B, Kuy C, Okada L, Hester KD, Bray KR, Mimms L, Jain A, Singh S, Collins A, Valasek MA, Sandborn WJ, Vermeire S, Dulai PS. Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. Gastroenterology 2020; 158: 515-526. e10. [PMID: 31711925 DOI: 10.1053/j.gastro.2019.10.034] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 13.5] [Reference Citation Analysis]
14 Grover Z, Burgess C, Muir R, Reilly C, Lewindon PJ. Early Mucosal Healing with Exclusive Enteral Nutrition is Associated with Improved Outcomes in Newly Diagnosed Children with Luminal Crohn’s disease. ECCOJC 2016;10:1159-64. [DOI: 10.1093/ecco-jcc/jjw075] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 10.0] [Reference Citation Analysis]
15 Dubcenco E, Zou G, Stitt L, Baker JP, Jeejeebhoy KN, Kandel G, Kim Y, Grover SC, Mcdonald JWD, Shackelton LM, Khanna R, D’haens G, Sandborn WJ, Feagan BG, Levesque BG. Effect of Standardised Scoring Conventions on Inter-rater Reliability in the Endoscopic Evaluation of Crohn’s Disease. ECCOJC 2016;10:1006-14. [DOI: 10.1093/ecco-jcc/jjw120] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
16 Alfaro I, Masamunt MC, Planell N, López-García A, Castro J, Gallego M, Barastegui R, Giner A, Vara A, Salas A, Ricart E, Panés J, Ordás I. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn’s disease. World J Gastroenterol 2019; 25(14): 1764-1774 [PMID: 31011260 DOI: 10.3748/wjg.v25.i14.1764] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Wang Z, Verstockt B, Sabino J, Vermeire S, Ferrante M, Declerck P, Dreesen E. Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease. Br J Clin Pharmacol 2021. [PMID: 34197653 DOI: 10.1111/bcp.14971] [Reference Citation Analysis]
18 Olesen CM, Coskun M, Peyrin-Biroulet L, Nielsen OH. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacol Ther. 2016;159:110-119. [PMID: 26808166 DOI: 10.1016/j.pharmthera.2016.01.001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 12.4] [Reference Citation Analysis]
19 Moy MP, Sauk J, Gee MS. The Role of MR Enterography in Assessing Crohn's Disease Activity and Treatment Response. Gastroenterol Res Pract 2016;2016:8168695. [PMID: 26819611 DOI: 10.1155/2016/8168695] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
20 Mitselos IV, Christodoulou DK, Katsanos KH, Tsianos EV. Role of wireless capsule endoscopy in the follow-up of inflammatory bowel disease. World J Gastrointest Endosc 2015; 7(6): 643-651 [PMID: 26078832 DOI: 10.4253/wjge.v7.i6.643] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
21 Asgharpour A, Cheng J, Bickston SJ. Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial. Clin Exp Gastroenterol 2013;6:153-60. [PMID: 24039442 DOI: 10.2147/CEG.S35163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.1] [Reference Citation Analysis]
22 Dreesen E, Berends S, Laharie D, D'Haens G, Vermeire S, Gils A, Mathôt R. Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease. Br J Clin Pharmacol 2021;87:106-18. [PMID: 32415677 DOI: 10.1111/bcp.14364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Reinink AR, Lee TC, Higgins PD. Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease: A meta-analysis. Inflamm Bowel Dis. 2016;22:1859-1869. [PMID: 27206015 DOI: 10.1097/mib.0000000000000816] [Cited by in Crossref: 61] [Cited by in F6Publishing: 21] [Article Influence: 20.3] [Reference Citation Analysis]
24 Cozijnsen MA, Samsom JN, de Ridder L. Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn's Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability. Paediatr Drugs 2018;20:19-28. [PMID: 29079905 DOI: 10.1007/s40272-017-0266-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Gordic S, Bane O, Kihira S, Peti S, Hectors S, Torres J, Cho J, Colombel JF, Taouli B. Evaluation of ileal Crohn's disease response to TNF antagonists: Validation of MR enterography for assessing response. Initial results. Eur J Radiol Open 2020;7:100217. [PMID: 33102636 DOI: 10.1016/j.ejro.2020.01.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
26 Sauer CG, Middleton JP, McCracken C, Loewen J, Braithwaite K, Alazraki A, Martin DR, Kugathasan S. Magnetic resonance enterography healing and magnetic resonance enterography remission predicts improved outcome in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2016;62:378-383. [PMID: 26348683 DOI: 10.1097/mpg.0000000000000976] [Cited by in Crossref: 28] [Cited by in F6Publishing: 6] [Article Influence: 5.6] [Reference Citation Analysis]
27 Watanabe K, Matsumoto T, Hisamatsu T, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group. Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2018;16:542-549.e1. [PMID: 29104132 DOI: 10.1016/j.cgh.2017.10.036] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
28 Bossuyt P, Louis E, Mary JY, Vermeire S, Bouhnik Y. Defining Endoscopic Remission in Ileocolonic Crohn's Disease: Let's Start from Scratch. J Crohns Colitis. 2018;12:1245-1248. [PMID: 29982528 DOI: 10.1093/ecco-jcc/jjy097] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
29 Sasaki T, Kunisaki R, Kinoshita H, Yamamoto H, Kimura H, Hanzawa A, Shibata N, Yonezawa H, Miyajima E, Sakamaki K. Use of color Doppler ultrasonography for evaluating vascularity of small intestinal lesions in Crohn’s disease: correlation with endoscopic and surgical macroscopic findings. Scand J Gastroenterol. 2014;49:295-301. [PMID: 24344807 DOI: 10.3109/00365521.2013.871744] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
30 Sobczak M, Fabisiak A, Murawska N, Wesołowska E, Wierzbicka P, Wlazłowski M, Wójcikowska M, Zatorski H, Zwolińska M, Fichna J. Current overview of extrinsic and intrinsic factors in etiology and progression of inflammatory bowel diseases. Pharmacol Rep 2014;66:766-75. [PMID: 25149979 DOI: 10.1016/j.pharep.2014.04.005] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 8.1] [Reference Citation Analysis]
31 Chen JM, Liu T, Gao S, Tong XD, Deng FH, Nie B. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China. World J Gastroenterol 2017; 23(46): 8235-8247 [PMID: 29290660 DOI: 10.3748/wjg.v23.i46.8235] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
32 Moy MP, Kaplan JL, Moran CJ, Winter HS, Gee MS. MR Enterographic Findings as Biomarkers of Mucosal Healing in Young Patients With Crohn Disease. AJR Am J Roentgenol 2016;207:896-902. [PMID: 27351067 DOI: 10.2214/AJR.16.16079] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
33 Hall B, Holleran G, Chin J, Smith S, Ryan B, Mahmud N, Mcnamara D. A prospective 52week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy. Journal of Crohn's and Colitis 2014;8:1601-9. [DOI: 10.1016/j.crohns.2014.09.005] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 8.4] [Reference Citation Analysis]
34 Deepak P, Bruining DH. Update on the Medical Management of Crohn's Disease. Curr Gastroenterol Rep 2015;17:41. [PMID: 26363802 DOI: 10.1007/s11894-015-0465-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
35 Dubé PE, Liu CY, Girish N, Washington MK, Polk DB. Pharmacological activation of epidermal growth factor receptor signaling inhibits colitis-associated cancer in mice. Sci Rep 2018;8:9119. [PMID: 29904166 DOI: 10.1038/s41598-018-27353-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
36 Frey MR, Brent Polk D. ErbB receptors and their growth factor ligands in pediatric intestinal inflammation. Pediatr Res 2014;75:127-32. [PMID: 24402051 DOI: 10.1038/pr.2013.210] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
37 Liu J, Dlugosz A, Neumann H. Beyond white light endoscopy: The role of optical biopsy in inflammatory bowel disease. World J Gastroenterol 2013; 19(43): 7544-7551 [PMID: 24282344 DOI: 10.3748/wjg.v19.i43.7544] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
38 Lerchova T, Hradsky O, Copova I, Potuznikova K, Gonsorcikova L, Bronsky J. The Accuracy of a Home-performed Faecal Calprotectin Test in Paediatric Patients With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019;69:75-81. [PMID: 30908389 DOI: 10.1097/MPG.0000000000002331] [Reference Citation Analysis]
39 Eder P, Łykowska-Szuber L, Katulska K, Stawczyk-Eder K, Krela-Kaźmierczak I, Klimczak K, Szymczak A, Stajgis M, Linke K. Intestinal healing after anti-TNF induction therapy predicts long-term response to one-year treatment in patients with ileocolonic Crohn's disease naive to anti-TNF agents. Prz Gastroenterol 2016;11:187-93. [PMID: 27713781 DOI: 10.5114/pg.2015.55185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
40 D’Incà R, Caccaro R. Measuring disease activity in Crohn’s disease: what is currently available to the clinician. Clin Exp Gastroenterol. 2014;7:151-161. [PMID: 24876789 DOI: 10.2147/ceg.s41413] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
41 Salvador-Martín S, López-Cauce B, Nuñez O, Laserna-Mendieta EJ, García MI, Lobato E, Abarca-Zabalía J, Sanjurjo-Saez M, Lucendo AJ, Marín-Jiménez I, Menchén LA, López-Fernández LA. Genetic predictors of long-term response and trough levels of infliximab in crohn's disease. Pharmacol Res 2019;149:104478. [PMID: 31605784 DOI: 10.1016/j.phrs.2019.104478] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
42 Hall BJ, Holleran GE, Smith SM, Mahmud N, Mcnamara DA. A prospective 12-week mucosal healing assessment of small bowel Crohn’s disease as detected by capsule endoscopy. European Journal of Gastroenterology & Hepatology 2014;26:1253-9. [DOI: 10.1097/meg.0000000000000194] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
43 Hall B, Holleran G, McNamara D. PillCam COLON 2© as a pan-enteroscopic test in Crohn’s disease. World J Gastrointest Endosc 2015; 7(16): 1230-1232 [PMID: 26566430 DOI: 10.4253/wjge.v7.i16.1230] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
44 Lopetuso LR, Gerardi V, Papa V, Scaldaferri F, Rapaccini GL, Gasbarrini A, Papa A. Can We Predict the Efficacy of Anti-TNF-α Agents? Int J Mol Sci 2017;18:E1973. [PMID: 28906475 DOI: 10.3390/ijms18091973] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 10.8] [Reference Citation Analysis]
45 Rimola J, Fernàndez-Clotet A, Capozzi N, Rojas-Farreras S, Alfaro I, Rodríguez S, Masamunt MC, Ricart E, Ordás I, Panés J. Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease. Aliment Pharmacol Ther 2020;52:1563-73. [PMID: 32886809 DOI: 10.1111/apt.16069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Santha SL, Shankar PR, Pan A, Schoen B, Kugathasan S, Sauer CG. Mucosal Healing in Clinical Practice: A Single-Center Pediatric IBD Experience. Inflammatory Bowel Diseases 2017;23:1447-53. [DOI: 10.1097/mib.0000000000001176] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
47 Feng T, Chen B, Ungar B, Qiu Y, Zhang S, He J, Lin S, He Y, Zeng Z, Ben-Horin S, Chen M, Mao R. Association of Infliximab Levels With Mucosal Healing Is Time-Dependent in Crohn's Disease: Higher Drug Exposure Is Required Postinduction Than During Maintenance Treatment. Inflamm Bowel Dis. 2019;25:1813-1821. [PMID: 30934050 DOI: 10.1093/ibd/izz061] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
48 Kang B, Choi SY, Kim HS, Kim K, Lee YM, Choe YH. Mucosal Healing in Paediatric Patients with Moderate-to-Severe Luminal Crohn’s Disease Under Combined Immunosuppression: Escalation versus Early Treatment. ECCOJC 2016;10:1279-86. [DOI: 10.1093/ecco-jcc/jjw086] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 7.6] [Reference Citation Analysis]